FibroBiologics Inc. (NASDAQ: FBLG) announced that it has dosed the first patients in a Phase 1/2 clinical trial evaluating CYWC628 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE